New financial instruments need to be developed to support innovative manufacturing. "There are no off-the-shelf solutions, but it is strategic to start building them now." Europe's industrial autonomy is at stake.

Why Neo-Industrial Companies Are a Different Kind of Being.
There are two fundamentally different kinds of industrial organization in the world today. Not two strategies, not two business models, not two corporate cultures: two different kinds of being.

Deep tech solved discovery. It never solved industrialization. The Neo-Industrial age is what comes next — and it demands a completely different kind of company.

New partnership combines real-time single-cell analysis with AI-driven biomanufacturing to close one of the field's longest-standing data gaps.

After evaluating over 300 molecules across 40 chemical families, the AB4S coalition has identified four priority families, terpenes, peptides, non-catalytic proteins, and hydroxy acids, as the most viable near-term opportunities for bio-based production.

The maps that mattered in the Age of Discovery were geographic. The maps that matter now are cognitive and are in need of an update.

On December 9th 2025, Arsenale CEO Massimo Portincaso took part in a panel at the Italian parliament on the industrial opportunity of biomanufacturing and what Italy must do to seize it.

Named one of the 100 most promising global impact ventures, Arsenale is part of a new generation of companies rethinking how we build, scale, and govern the systems that shape our future.

The Pordenone-based startup is accelerating its growth thanks to a multi-million euro capital increase. It now plans to connect with Veneto universities and industries.

Biotech’s barriers to scale aren’t accidental – they’re structural.
To unlock the bioeconomy, we must design out the bottlenecks in infrastructure, translation, and capital from the start.

Biotech’s frontier is no longer technical – it’s economic.
To scale, we must design industrial systems where viability is built in from the start, not added as an afterthought.

In this Leaders on a Mission podcast episode, Massimo Portincaso joins Simon Leich to explore why the future of biomanufacturing depends on modular systems, economies of learning, and rethinking the logic of scale entirely.

Breakthroughs in precision fermentation, strain design, and process optimization have reshaped the edges of what’s possible. Yet much of industrial biotech remains stalled – technically sound but economically unviable.

In this essay, Massimo Portincaso explores how biomanufacturing, and particularly precision fermentation, signals more than a technological breakthrough. It marks the rise of a new industrial logic – one no longer centered on extraction, but on nature co-design.

When we chose the name Arsenale, we were not looking for a metaphor. We were aligning our mission.

Despite the massive improvements in scale-up enabled by single-use bioreactors and a scale-out philosophy, going from process development scale to larger bioreactors remains tricky.

Arsenale Bioyards has been selected as a 2025 Technology Pioneer by the World Economic Forum.

Biotechnology holds immense promise, yet its full potential remains untapped. To bridge this gap, the industry must embrace strategic shifts that streamline processes and enhance scalability. Central to this transformation are three pivotal strategies.

Arsenale is building a neo-industrial biomanufacturing company – one that integrates modular infrastructure, advanced sensing, and AI-enabled design to radically transform how biology is deployed at scale. As Chief Operating Officer, Arnaud Legris is connecting the dots across a complex system, with an evolving role as the company grows.

Precision fermentation represents a frontier in biotechnology, offering a sustainable method for producing high-value compounds. However, its widespread adoption beyond high-value compounds hinges on achieving cost parity with traditional production methods (and/or better performance).